Product image of Malarone (Proguanil Hydrochloride, Atovaquone) supplied by GNH India

Malarone

Active Ingredient:
Proguanil Hydrochloride, Atovaquone
Origin:
EU

Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil tablet for oral use. It treats and prevents malaria caused by Plasmodium falciparum and Plasmodium vivax in travelers, expatriates, and residents of endemic regions.

GNH India supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory compliance to ensure product integrity. Malarone is manufactured under EU GMP guidelines and distributed to a global network of healthcare providers.

Manufacturer / TM Owner

Glaxosmithkline - Produtos Farmaceuticos, Lda

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Malarone (atovaquone/proguanil) is used in the prevention and treatment of malaria, an infectious disease caused by Plasmodium parasites.

  • Prevention of malaria (travel prophylaxis): provides protective antimalarial activity for individuals traveling to or residing in endemic areas.
  • Treatment of acute uncomplicated malaria (Plasmodium falciparum): clears infection and resolves symptoms in patients with confirmed falciparum malaria.
  • Treatment of acute uncomplicated malaria (Plasmodium vivax): effective against blood‑stage infection of vivax malaria.

How It Works

  • Atovaquone inhibits mitochondrial electron transport in Plasmodium parasites, disrupting ATP synthesis, while proguanil interferes with folate metabolism by inhibiting dihydrofolate reductase. The combination produces a synergistic antimalarial effect that blocks parasite replication at the blood stage.

Side Effects

Malarone may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal pain, or diarrhea.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional sensation of light‑headedness.
  • Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects

  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Blood dyscrasias: neutropenia, thrombocytopenia, or anemia.
  • Hypersensitivity: anaphylaxis or severe allergic reactions.

Precautions & Warnings

Before prescribing Malarone, consider the following safety measures.

  • Pregnancy: safety not established; use only if benefit outweighs risk.
  • Renal impairment: dose adjustment may be required; monitor renal function.
  • Hepatic impairment: use with caution; monitor liver enzymes.
  • Concomitant antiretrovirals: may reduce efficacy; assess drug interactions.
  • Travel to high‑risk areas: ensure adequate prophylactic regimen and adherence.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Malarone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Rifampin: induces metabolism and reduces plasma concentrations of both components, compromising efficacy.
  • CYP2C8 inhibitors (e.g., gemfibrozil): increase atovaquone levels, raising risk of toxicity.
  • Protease inhibitors (e.g., ritonavir): may increase proguanil concentrations, leading to adverse effects.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may decrease atovaquone absorption; separate dosing by at least 2 hours.
  • Warfarin: proguanil may potentiate anticoagulant effect; monitor INR.
  • Macrolide antibiotics (e.g., erythromycin): may increase proguanil concentrations; observe for side effects.

Frequently Asked Questions

Malarone is indicated for the prevention of malaria in travelers and residents of endemic regions, as well as for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax.

The combination pairs atovaquone, which blocks mitochondrial electron transport in the parasite, with proguanil, which inhibits folate metabolism via dihydrofolate reductase inhibition. Together they produce a synergistic effect that stops parasite replication in the blood stage.

The dosage of Malarone is determined by a qualified prescriber based on the indication, patient weight, age, and renal or hepatic function. Patients should follow the exact regimen prescribed by their healthcare professional.

Safety of Malarone in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To order Malarone, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a convenient once‑daily oral regimen with a dual mechanism of action, providing high efficacy against chloroquine‑resistant strains. Alternatives such as doxycycline or mefloquine have different dosing schedules and side‑effect profiles, making Malarone a preferred choice for many travelers when tolerated.

Malarone tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Protect them from moisture and direct light to maintain stability throughout their shelf life.

Malarone is taken orally with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, continued daily during exposure, and continued for 7 days after leaving the area. Treatment regimens follow the prescriber’s instructions.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, blood‑cell abnormalities, and hypersensitivity reactions including anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, unexplained bruising, or signs of an allergic reaction.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in pregnant women unless the benefit outweighs the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Proguanil Hydrochloride, Atovaquone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT